Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors

Ben Ponvilawan,Abdul Wali Khan,Janakiraman Subramanian,Dhruv Bansal

DOI: https://doi.org/10.3390/cancers16061225

2024-03-21

Cancers

Abstract:Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months of treatment, and 11% develop severe irAEs requiring interventions. A predictive test for irAEs would be a crucial tool for monitoring for complications during and after ICI therapy. We performed an extensive review of potential predictive biomarkers for irAEs in patients who received ICI therapy. Currently, only thyroid-stimulating hormone is utilized in common clinical practice. This is due to the unavailability of commercial tests and unclear predictive values from various studies. Given the lack of single strong predictive biomarkers, some novel approaches using composite scores using genomic, transcriptomics, cytokine levels, or clinical parameters appear appealing. Still, these have yet to be validated and incorporated into clinical practice. Further research conducted to validate the models before implementing them into real-world settings will be of the utmost importance for irAE prediction.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the prediction of immune - related adverse events (irAEs) that occur during immune checkpoint inhibitor (ICIs) treatment. Although approximately 40% of patients receiving ICIs treatment will experience irAEs within five months after treatment, currently only thyroid function tests are widely used to predict these adverse reactions. Through an extensive literature review, the paper explores a variety of potential non - invasive predictive biomarkers, aiming to improve the predictive ability of irAEs, so as to better monitor and manage the complications of cancer patients receiving ICIs treatment.

Specifically, the paper focuses on the following aspects:

1. **Evaluation of existing predictive biomarkers**: The paper comprehensively evaluates various existing biomarkers for predicting irAEs, including autoantibodies, blood cell counts, cell - type ratios, lymphocyte subset characteristics, cytokine and chemokine levels, human leukocyte antigen (HLA) variations, single - nucleotide polymorphisms (SNPs), and other potential biomarkers.

2. **Differences in different ICI treatment regimens**: The paper also discusses the differences in irAEs predictive biomarkers among different types of ICIs (such as anti - PD(L)1 treatment and anti - CTLA - 4 treatment), pointing out that some biomarkers may be more effective for specific types of ICIs.

3. **Future research directions**: Given the current lack of a single powerful predictive biomarker, the paper proposes some new methods, such as using comprehensive scoring systems of genomics, transcriptomics, cytokine levels, or clinical parameters, and emphasizes the need for further research to validate these models in order to apply them in actual clinical practice.

Overall, this paper aims to provide a scientific basis for the development of more effective irAEs prediction tools through systematic review and analysis of existing research, with the expectation of improving the management and treatment outcomes of cancer patients receiving ICI treatment.